Madrigal Pharmaceuticals, Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual filing, not a standalone fourth-quarter report; quarterly figures below are included where relevant. Madrigal was a clinical-stage biopharmaceutical company with no product revenue, focused primarily on developing resmetirom for NASH.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $72.3 million | $25.4 million |
| General and administrative expense | $22.6 million | $15.3 million |
| Total operating expenses / operating loss | $95.0 million | $40.7 million |
| Interest income | $11.0 million | $7.7 million |
| Net loss | $83.9 million | $32.8 million |
| Basic and diluted loss per share | $5.45 | $2.22 |
| Cash, cash equivalents and marketable securities at year-end | $439.0 million | $483.7 million |
| Total liabilities at year-end | $25.5 million | $8.4 million |
- Net cash used in operating activities was $41.6 million, up from $25.5 million in 2018, primarily reflecting increased clinical-trial activity. Investing activities provided $30.7 million, largely from marketable-security maturities and sales; financing activities provided $0.2 million.
- Cash and investments were primarily short-duration, high-quality securities. Management said available resources were expected to fund operations for more than one year from issuance of the financial statements; the company expected continued losses and said additional capital could be needed.
- No material borrowings are identified in the provided filing text. Year-end liabilities included $23.6 million of accrued expenses and $0.7 million of lease liabilities. Contractual operating-lease payments totaled $0.8 million.
- Operating margins are not meaningful because the company had no revenue. The $83.9 million accumulated deficit reflects ongoing development-stage losses.
Business progress and changes versus 2018
- Madrigal initiated the Phase 3 MAESTRO-NASH trial in March 2019. It planned to enroll approximately 2,000 patients; the first 900 patients’ Week 52 biopsies were intended to support a potential accelerated-approval application. The study also includes longer-term clinical-outcome follow-up.
- In December 2019, Madrigal opened enrollment in MAESTRO-NAFLD-1, a 700-patient, 52-week Phase 3 study focused on safety and biomarker endpoints, including an open-label arm of up to 100 patients.
- The FDA granted resmetirom Fast Track designation for NASH in October 2019. This is not marketing approval and does not assure approval or a particular review outcome.
- Research and development expense rose 185% year over year, driven mainly by Phase 3 activity, manufacturing work, increased headcount, stock-based compensation and a $2 million Roche milestone payment. General and administrative expense increased 48%, primarily due to stock-based compensation.
- The 2018 comparative period included $311.8 million of net proceeds from a common-stock offering; 2019 financing cash flow was minimal. Cash and investments declined by $44.7 million during 2019.
Clinical evidence, outlook and risks
- In the completed Phase 2 NASH study, resmetirom met its 12-week liver-fat primary endpoint. Reported 36-week results included improvements in liver-fat and lipid measures and statistically significant results on certain biopsy-based NASH endpoints. These Phase 2 findings do not establish Phase 3 success or regulatory approval.
- Management expected R&D and G&A expenses to rise as development advanced. Madrigal had no sales, marketing or manufacturing infrastructure and relied on third parties for clinical-trial services and drug manufacturing.
- Key uncertainties include whether Phase 3 trials demonstrate sufficient efficacy and long-term safety; enrollment, trial execution and regulatory requirements; whether accelerated approval is available and post-approval outcomes are confirmed; competition; manufacturing and supply; intellectual-property protection; and future financing, commercialization, coverage and reimbursement.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management and the auditor concluded that internal control over financial reporting was effective as of year-end.
- The filing discussed the newly emerging coronavirus outbreak as a potential risk to business activities, including China-related manufacturing and supply-chain activities; the extent of any impact was uncertain.
Most important facts for investors to verify
- Current enrollment, timing and results for MAESTRO-NASH and MAESTRO-NAFLD-1, including the prespecified biopsy endpoints and long-term outcomes.
- Whether $439.0 million of year-end cash and investments remains sufficient given the company’s rising operating cash use and planned development spending.
- Actual future R&D spending, milestone obligations to Roche, and any need for additional equity, debt or partnership financing.
- Long-term safety data, regulatory feedback and the eventual scope and conditions of any resmetirom approval; Fast Track designation is not approval.
- Potential dilution from outstanding options and convertible preferred shares, as well as the ability to secure manufacturing capacity and commercially viable reimbursement if a product is approved.